This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
29
Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
RECRUITINGDisease control rate (DCR) based on RECIST v. 1 1
Disease control rate (DCR) based on RECIST v. 1 1 by investigators
Time frame: 6 weeks
Objective response rate (ORR) based on RECIST V. 1.1
Objective response rate (ORR) based on RECIST V. 1.1 by investigators
Time frame: 6 weeks
Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression
Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression by investigators assessment
Time frame: 6 weeks
Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause
Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause by investigators assessment
Time frame: 6 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.